SI-BONE (NASDAQ:SIBN) issued its quarterly earnings data on Sunday. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.03, MarketWatch Earnings reports. SI-BONE had a negative net margin of 61.67% and a negative return on equity of 45.03%.
SI-BONE stock traded down $2.88 during trading hours on Tuesday, reaching $33.08. 25,822 shares of the company were exchanged, compared to its average volume of 287,842. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -20.62 and a beta of 1.41. The company has a current ratio of 12.65, a quick ratio of 12.22 and a debt-to-equity ratio of 0.39. The stock has a 50-day moving average of $33.10 and a 200 day moving average of $28.78. SI-BONE has a 12 month low of $14.37 and a 12 month high of $36.78.
Several equities research analysts have commented on the stock. Needham & Company LLC boosted their price target on shares of SI-BONE from $34.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist boosted their price objective on SI-BONE from $35.00 to $43.00 in a report on Tuesday. Zacks Investment Research cut SI-BONE from a “hold” rating to a “sell” rating in a research note on Friday, March 12th. Canaccord Genuity boosted their price target on SI-BONE from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Truist Securities boosted their price target on SI-BONE from $35.00 to $43.00 in a research note on Tuesday. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $36.63.
In other news, CFO Laura Francis sold 18,358 shares of the company’s stock in a transaction that occurred on Thursday, March 18th. The stock was sold at an average price of $33.34, for a total transaction of $612,055.72. Following the completion of the transaction, the chief financial officer now directly owns 197,471 shares in the company, valued at $6,583,683.14. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jeffrey W. Dunn sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, March 5th. The stock was sold at an average price of $28.65, for a total value of $1,146,000.00. The disclosure for this sale can be found here. Insiders have sold 1,067,472 shares of company stock valued at $32,658,438 in the last ninety days. Company insiders own 15.50% of the company’s stock.
SI-BONE Company Profile
SI-BONE, Inc, a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.
Featured Article: How do CD ladders protect against rising interest rates?